Carrie Robertson, MD
Neurology · Rochester, MNNPI 1609888270
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,331 of the $10,864 with a category attached, or 76.7%. Lundbeck LLC accounts for 85.9% of it on its own, with 5 other manufacturers making up the rest.
Across 25 payments — averaging $434.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$9K
- AbbVie$1K
- Biodelivery Sciences International, Inc.$46
- Biohaven Pharmaceutical Holding Company Ltd.$39
- Teva Pharmaceuticals USA, Inc.$34
- Novo Nordisk$28
Across 96 payments — averaging $2804.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$174K
- H. Lundbeck A S$61K
- Teva Pharmaceuticals USA, Inc.$34K
What the payments were for
- Consulting fees$8,33177%
- Travel & lodging$1,37013%
- Food & beverage$1,16311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 9 | $9,328 |
| AbbVie | 11 | $1,388 |
| Biodelivery Sciences International, Inc. | 1 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Novo Nordisk | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,864 in reported general payments places this provider in the 85th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $8,001 |
| Amitriptyline Hcl | 15 | $489 |
| Metoprolol Succinate | 21 | $354 |
| Gabapentin | 17 | $313 |
| Prasugrel Hcl | 11 | $143 |
| Topiramate | 12 | $107 |
| Carvedilol | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Wolfgang SingerRochester$128K
- Ronald PetersenRochester$126K
- Partha GhoshRochester$121K
- Eoin FlanaganRochester$55K
- Keith CoffmanRochester$24K
- Igal MirmanRochester$18K
- P James DyckRochester$17K
- Suresh KotagalRochester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.